Results
Agitation, COPD, ARDS
ACUTE RESPIRATORY DISTRESS SYNDROME, COPD, ARDS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE
A total of 635 patients were screened, and 60 patients were randomized (Fig. Patient screening, enrollment, and randomizationDemographic and clinical characteristics of the patients at baselineData are number (%), mean (SD), or median (interquartile range)APACHE II: Acute Physiology and Chronic Health Evaluation II; ARDS: Acute Respiratory Distress Syndrome; BMI: Body Mass Index; COPD: Chronic Obstructive Pulmonary Disease; FiOThe median (IQR) intervention period was 48.0 (21.5, 48.0) hours in the remimazolam group and 28.0 (23.5, 48.0) hours in the propofol group. The median (IQR) infusion rate of remimazolam besylate and propofol were 0.60 (0.45, 1.07) mg/kg/h and 2.53 (1.94, 2.94) mg/kg/h, respectively. Remifentanil infusion rate and the requirement of rescue sedation were similar between groups. The median percentage of time within the target RASS score was 100% in the two groups (Table Intervention, sedation monitoring, and study outcomesData are number (%), mean (SD), or median (interquartile range)ICU: Intensive Care Medicine; RASS: Richmond Agitation and Sedation ScalePercentage of Richmond Agitation Sedation Scale (RASS) assessmentsAt 7 days after enrollment, 35 (58.3%) patients were still in ICU, 13 (21.7%) were discharged from ICU to general ward, 7 (11.7%) were transferred to other hospitals, and 5 (8.3%) died. No significant differences were observed in ventilator-free hours within 7 days, successful extubation, length of ICU stay, or 28-day mortality (Table 